<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1005233624
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VPRIV 40 U POWDER FOR SOLUTION FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VELAGLUCERASE ALFA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        U
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6118.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Cangene BioPharma Inc. (CBI) " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Cangene BioPharma Inc. (CBI) 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Takeda Pharmaceuticals International AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>VPRIV is a hydrolytic lysosomal glucocerobroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for paediatric and adult patients with type 1 Gaucher disease. Gaucher disease is a genetic disorder caused by a missing or defective enzyme named glucocerebrosidase. When this enzyme is missing or does not work properly, a substance called glucocerebroside builds up inside cells in the body. The build-up of this material causes the signs and symptoms found in Gaucher disease.</p><p>VPRIV is designed to replace the missing or defective enzyme, glucocerebrosidase, in patients with Gaucher disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>If you are allergic to velaglucerase alfa or any of the other ingredients of this medicine.</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor before using VPRIV</p><ul><li>If you are treated with VPRIV, you may experience a side effect during or following the infusion [see section 4, possible side effects). This is known as an infusion-related reaction and can sometimes be severe.</li><li>Infusion-related reactions include dizziness, headache, nausea, low or high blood pressure, tiredness, and fever. If you experience an infusion-related reaction, you must tell your doctor immediately.</li><li>If you have an infusion-related reaction you may be given additional medicines to treat or help prevent future reactions. These medicines may include antihistamines, antipyretics, and corticosteroids.</li><li>If the infusion-related reaction is severe, your doctor will stop the intravenous infusion immediately and start giving you appropriate medical treatment.</li><li>If the infusion related reactions are severe and/or there is a loss of effect from this medicine, your doctor will perform a blood test to check for antibodies which may affect the outcome of your treatment</li><li>Most of the time you can still be given VPRIV even if you experience an infusion-related reaction.</li></ul><p>Tell your doctor if you have previously experienced an infusion-related reaction or allergic reaction with other ERT for Gaucher disease.</p><p>&nbsp;</p><p><strong>Children</strong><br />VPRIV should not be used in children under the age of 2 years.<br />&nbsp;</p><p><strong>Taking other medicines</strong><br />Tell your doctor if you are taking, have recently taken or might take any other medicines including medicines obtained without prescription.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before<br />taking this medicine.</p><p>Gaucher disease may become more active in a woman during pregnancy and for a few weeks after birth. Women with Gaucher disease who are considering pregnancy should talk with their doctor.</p><p>VPRIV has not been studied in pregnant women. Studies in animals do not show harmful effects from VPRIV. Caution should be exercised when using VPRIV in pregnancy.</p><p>VPRIV has not been studied in women who are breast-feeding and it is not known whether VPRIV appears in breast milk. However, VPRIV contains a protein that may be digested by the child. Cautious use of VPRIV during breast feeding is recommended.<br />Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong><br />VPRIV has no or negligible influence on your ability to drive or use machines.<br />&nbsp;</p><p><strong>Important information about some of the ingredients of VPRIV</strong><br />VPRIV contains sodium. Each 400 Units vial of this medicine contains 12.15 mg sodium. This should be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>VPRIV is only to be used under appropriate medical supervision of a doctor who is knowledgeable in the treatment of Gaucher disease. VPRIV is given by a doctor or nurse by intravenous infusion.</p><p><strong>Dose</strong><br />The recommended dose is 60 Units/kg given every other week. If you are currently being treated for Gaucher disease with another ERT and your doctor wants to change you to VPRIV, you can initially receive VPRIV at the same dose and frequency you had been receiving the other ERT. In clinical studies, doses ranging from 15 Units/kg to 60 Units/kg have been used.</p><p><strong>Use In children and adolescents</strong><br />VPRIV may be given to children and adolescents (2 to 17 years of age) at the same dose and frequency as in adults.</p><p><strong>Use In elderly</strong><br />VPRIV may be given to the elderly (aged over 65 years) at the same dose and frequency as in adults.<br />&nbsp;</p><p><strong>Response to treatment</strong><br />Your doctor will monitor your response to treatment and may change your dose (up or down) over time.<br />If you are tolerating your infusions well in the clinic, your doctor or nurse may administer your infusions at home.</p><p><strong>Administration</strong><br />VPRIV is supplied in a vial as a packed powder which is mixed with sterile water and further diluted in sodium chloride 9 mg/ml (0.9%) solution prior to intravenous infusion.<br />After preparation, your doctor or nurse will give VPRIV to you through a drip into a vein (by intravenous infusion) over a period of 60 minutes.<br />&nbsp;</p><p><strong>If you use more VPRIV than you should</strong><br />If you feel ill whilst receiving the infusion, tell your doctor or nurse immediately.<br />&nbsp;</p><p><strong>If you forget to use VPRIV</strong><br />If you have missed an infusion, please contact your doctor.<br />&nbsp;</p><p><strong>If you stop using VPRIV</strong><br />Discuss changes in treatment with your doctor.</p><p>If you have any further questions on the use of this medicine, ask<br />your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>However a few patients experienced an allergic skin reaction such as severe rash or itching. A severe allergic reaction, with difficulty breathing, swelling of the face, lips, tongue or throat occurred. If any of these happen tell your doctor immediately.</p><p>In studies with VPRIV, most side effects occurred during the infusion or shortly after. These are called infusion-related reactions and include;</p><ul><li>headache</li><li>dizziness</li><li>fever/body temperature increased</li><li>decreased blood pressure or increased blood pressure</li><li>nausea and tiredness.</li></ul><p>If you experience any side effect like these, please tell your doctor immediately. The majority of these side effects were mild in intensity.<br />In studies with VPRIV additional side effects have also been reported:<br />Very common side effects (affecting more than 1 person in 10) are:</p><ul><li>bone pain</li><li>joint pain</li><li>back pain</li><li>weakness/loss of strength/fatigue</li></ul><p>Common side effects (affecting less than 1 person in 10) are:</p><ul><li>abdominal pain/nausea</li><li>easy bleeding/ easy bruising</li><li>skin flushing</li><li>rapid heart beat</li><li>rash/hives</li><li>developing antibodies to VPRIV (see section 2).</li></ul><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep this medicine out of the sight and reach of children.</li><li>Do not use this medicine after the expiry date which is stated on the carton and label after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</li><li>Store in the refrigerator [2&deg;C to 8&deg;C).</li><li>Do not freeze.</li><li>Keep the vial in the outer carton in order to protect from light.</li><li>Do not use if the solution is discoloured or if foreign particles are present.</li><li>The medicinal product should be used immediately. If not used immediately use within 24 hours at 2&deg;C to 8&deg;C under protection from light.</li><li>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is velaglucerase alfa.</li></ul><p>One vial of VPRIV 400 Units powder contains 400 Units of velaglucerase alfa.<br />After reconstitution, one ml of solution contains 100 Units of velaglucerase alfa</p><ul><li>The other ingredients are sucrose, sodium citrate dihydrate, citric acid monohydrate, and polysorbate 20 (see section 2 &quot;VPRIV contains sodium&rdquo;).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vpriv is a white to off-white powder for solution for infusion.
Prior to dilution; the solution should be clear to slightly opalescent and colourless; do not use if the solution is discoloured, or if foreign particulate matter is present.
VPRIV is available in 20 ml glass vial containing 400 Units
velaglucerase alfa in the form of powder for solution for infusion.
Cartons with 1, 5 or 25 vials.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><br />Shire Pharmaceutical Ireland ltd<br />Block 2 &amp; 3 Miesian Plaza, 50-58 Baggot Street Lower<br />Dublin 2, D02 Y754, Ireland</p><p><strong>Manufacturers</strong><br />Cangene bioPharma, Inc. (CBI), 1111 South Paca Street,<br />Baltimore, MD 21230, USA<br />and<br />Vetter Pharma-Fertigung GmbH &amp; Co. KG<br />Mooswiesen 2<br />88214 Ravensburg<br />Germany<br /><strong>Batch releaser:</strong><br />Shire Pharmaceutical Ireland Ltd<br />For any information about this medicine or to report any side<br />effects in Lebanon and all MENA countries, please contact the<br />local representative of the Marketing Authorisation Holder:<br />Biologix FZ Co., Dubai Free Zone, Road WB 21, Warehouse C17,<br />PO Box 54405, Al Tawar, Dubai, United Arab Emirates.<br />Telephone no.: 00971 4 2997171<br />Email address: Pharmacovigilance@blgx.net</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in July 2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>إن فبريف، هو إنزيم متحلل بالماء، جلوكوسيريبروزيداز ليزوزومي محدد، وهو مخصص&nbsp;للعلاج بتعويض الإنزيم (ERT) على المدى الطويل للأطفال والبالغين من المرضى ، الذين &nbsp;يعانون من النوع الأول من داء غوشيه.</p><p><br />إن داء غوشيه، هو اضطراب وراثي ناجم عن نُقصان، أو خلل في إنزيم يُدعى جلوكوسيريبروزيداز. عندما يوجد نقص في هذا الإنزيم، أو عندما لا يؤدي عمله جيدًا، تتراكم مادة تسمى الجلوكوسيريبروزيد داخل خلايا الجسم. ويتسبب تراكم هذه المادة في ظهور علامات وأعراض داء غوشيه.<br />تم تصميم فبريف لاستبدال الإنزيم الناقص، أو غير العامل &ndash; جلوكوسيريبروزيداز &ndash; لدى المرضى الذين يعانون من داء غوشيه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع استخدام فبريف:</strong><br />إذا كان لديك حساسية من فيلاجلوسيراز ألفا (velaglucerase alfa) ، أو أي من المكونات الأخرى لهذا الدواء(المدرجة في القسم 6).<br />&nbsp;</p><p><strong>التحذيرات والاحتياطات:</strong><br />تشاور مع طبيبك قبل استخدام فبريف:</p><ul><li>إذا كنت تعالج ب فبريف، فقد تعاني من أحد الآثار الجانبية له، أثناء أو بعد الحقن (انظر إلى القسم 4، التأثيرات الجانبية المحتملة). ويعرف هذا برد الفعل المتعلق بالحقن ويمكن أن يكون خطيرًا في بعض الأحيان.</li><li>تتضمن ردود الفعل المتعلقة بالحقن: الدوار، الصداع، الغثيان، انخفاض أو ارتفاع ضغط الدم/التعب، والحمى. إذا عانيت من ردة فعل متعلقة بالحق، يتعين عليك إخبار طبيبك على الفور.</li><li>إذا كنت تعاني من ردة فعل متعلقة بالحق، قد يتم إعطاؤك أدوية إضافية؛ لعلاجها أو للمساعدة على منع حدوث ردود فعل في المستقبل. قد تشمل هذه&nbsp; الأدوية مضادات الهستامين، مضادات الحُمى، والكورتيكوستيرويدات.</li><li>إذا كانت ردة الفعل المتعلقة بالحقن خطيرة، فسوف يوقف طبيبك الحقن الوريدي على الفور، ويبدأ بإعطائك العلاج الطبي المناسب.</li><li>إذا كانت ردة الفعل المتعلقة بالحقن خطيرة و/أو كان الدواء غير فعال، فسيقوم طبيبك بإجراء فحص للدم؛ للتحقق من وجود أجسام مضادة قد تؤثر على نتائج علاجك.</li><li>يمكن أن يتم الاستمرار بإعطائك فبريف في معظم الأحيان، حتى لو كنت تعاني من ردة فعل متعلقة بالحقن.</li></ul><p>أخبر طبيبك؛ إذا كنت قد عانيت من قل من ردة فعل متعلقة بالحقن، أو من رد فعل تحسسي، مع أي علاج آخر بتعويض الإنزيم لداء غوشيه.</p><p><strong>الأطفال</strong></p><p>يجب ألا يعطى فبريف للأطفال الذين يقل عمرهم عن عامين.<br />&nbsp;</p><p><strong>التداخلات الدوائية من أخذ هذا الدواء مع أي أدوية أخرى</strong><br />أخبر طبيبك؛ إذا كنت تتناول أو تناولت مؤخرًا، أو قد تتناول أية أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها من دون وصفة طبية.</p><p><strong>الحمل والرضاعة</strong><br />اطلبي المشورة من طبيبك؛ قبل تناول هذا الدواء، إذا كنت حاملاً أو تُرضعين، أو تعتقدين أنك قد تكونين حاملاً، أو تخططين للإنجاب.<br />قد يصبح داء غوشيه أكثر نشاطًا عند النساء أثناء فترة الحمل، ولبضعة أسابيع بعد الولادة.<br />يتعين على النساء اللواتي يعانين من داء غوشيه، ويفكرن في الحمل أن يتحدثن مع طبيبهن. لم تتم دراسة تأثير فبريف على النساء الحوامل. ولم تُظهر الدراسات &ndash; على الحيوانات &ndash; أي آثار ضارة ل فبريف. وينبغي توخي الحذر؛ عند استخدام فبريف أثناء فترة الحمل.<br />لم تتم دراسة تأثير فبريف على النساء اللواتي يُرضعن، وليس معروفًا إذا ما كان فبريف يتسرب إلى حليب الثدي. ومع ذلك، فإن فبريف يحتوي على بروتين يمكن هضمه من قبل الطفل. ويوصى بالاستخدام الحذر ل فبريف أثناء فترة الرضاعة.<br />اطلبي المشورة من طبيبك، أو الصيدلي قبل تناول أي دواء.</p><p><strong>تأثيرات فبريف على القيادة واستخدام الآلات</strong><br />ليس ل فبريف أي تأثير، أو له تأثير لا يُذكر على قدرتك على القيادة أو استخدام الآلات.<br /><strong>معلومات هامة عن بعض مكونات فبريف</strong><br />يحتوي فبريف على الصوديوم. فكل قارورة بسعة 400 وحدة &ndash; من هذا الدواء &ndash; تحتوي على 12 .15 ملغ من الصوديوم. وينبغي على المرضى &ndash; الذين يتبعون نظامًا غذائيًا منخفض الصوديوم &ndash; أن يأخذوا ذلك في اعتبارهم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب أن يستخدم فبريف &ndash; فقط &ndash; تحت الإشراف الطبي المناسب، بواسطة طبيب على دراية بعلاج داء غوشيه. يتم إعطاء فبريف من قبل طبيب أو ممرضة عن طريق الحقن الوريدي.</p><p><strong>الجرعة</strong><br />الجرعة الموصى بها هي 60 وحدة/كلغ، تُعطى مرة كل أسبوعين.<br />إذا كنت تعالج حاليًا من داء غوشيه، بعلاج آخر بتعويض الإنزيم، ويريد طبيبك أن يغير العلاج ليستخدم فبريف، فيمكنك مبدئيًا تلقي فبريف بنفس الجرعة وبنفس التواتر &ndash; اللذين كنت تتلقي بهما العلاج الآخر بتعويض الإنزيم. لقد استخدمت جرعات تتراوح بين 15 وحدة/كلغ إلى 60 وحدة/كلغ في الدراسات السريرية.</p><p><strong>طريقة استخدام الدواء لدى الأطفال والمراهقين</strong><br />يمكن إعطاء فبريف للأطفال والمراهقين (الذين تتراوح أعمارهم ما بين عامين و 17 عامًا)، بنفس الجرعة وبنفس التواتر، كما هو الحال لدى البالغين.</p><p><strong>طريقة استخدام الدواء لدى كبار السن</strong><br />يمكن إعطاء فبريف لكبار السن (الذين تزيد أعمارهم عن 56 عامًا)، بنفس الجرعة وبنفس التواتر، كما هو الحال لدى البالغين.<br />&nbsp;</p><p><strong>الاستجابة للعلاج</strong><br />سوف يراقب طبيبك استجابتك للعلاج، وقد يغير جرعتك )زيادة أو نقصانًا( مع مرور الوقت يمكن أن يقوم طبيبك، أو ممرضتك بحقنك في المنزل؛ إذا كنت تتحمل الحقن بشكل جيد في العيادة.</p><p><strong>الحقن</strong><br />يتم توفير فبريف في قارورة، على شكل مسحوق مُعبأ، يتم خلطه بالماء المعقم، ويتم تخفيفه بشكل أكبر في محلول من كلوريد الصوديوم 9 ملغ/مل ( 0.9 %) قبل الحقن الوريدي.<br />بعد تحضير فبريف، سيقوم طبيبك أو ممرضتك بإعطائك إياه بواسطة التنقيط في الوريد (عن طريق الحقن الوريدي)، على مدى 60 دقيقة.</p><p><strong>الجرعة الزائدة من فبريف</strong><br />إذا شعرت بالغثيان أثناء تلقي الحقن &ndash; أخبر طبيبك أو ممرضتك على الفور.<br /><strong>نسيان تلقي جرعة فبريف</strong><br />إذا كنت قد نسيت تلقي جرعة من الدواء &ndash; يرجى الاتصال بطبيبك.</p><p><strong>التوقف عن تلقي فبريف</strong><br />ناقش التغييرات في العلاج مع طبيبك.</p><p>اسأل طبيبك؛ إذا كان لديك أي أسئلة أخرى حول تلقي هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل الأدوية كافة، يمكن أن يسبب هذا الدواء تأثيرات جانبية، ولكنها لا تصيب كل الناس. لكن عانى عدد قليل من المرضى، من رد فعل تحسسي في الجلد &ndash; مثل الطفح الجلدي، أو الحكة الشديدين. ويحدث رد الفعل التحسسي الخطير مع حدوث صعوبة في التنفس، تورم في الوجه والشفتين، واللسان، أو الحلق. أخبر طبيبك فورًا؛ إذا حدث شيء من هذا.</p><p>في دراسات تستخدم دواء فبريف، حدثت معظم التأثيرات الجانبية أثناء الحقن، أو بعد فترة وجيزة منه. وتسمى تلك التأثيرات الجانبية بردود الفعل المتعلقة بالحقن، وتشمل:</p><ul><li>الصداع</li><li>الدوار</li><li>الحمى/ زيادة درجة الحرارة الجسم</li><li>انخفاض ضغط الدم أو ارتفاع ضغط الدم</li><li>الغثيان والتعب</li></ul><p>يرجى إخبار طبيبك على الفور؛ إذا عانيت من أي تأثيرات جانبية، مثل تلك التأثيرات. كانت<br />معظم تلك التأثيرات الجانبية خفيفة الشدة.</p><p>كما تم الإبلاغ عن تأثيرات جانبية إضافية في دراسات تستخدم دواء فبريف:<br />التأثيرات الجانبية الشائعة جدًا (التي تصيب أكثر من فرد واحد من أصل كل 10 أفراد) هي:</p><ul><li>آلام العظام</li><li>آلام المفاصل</li><li>آلام الظهر</li><li>الضعف/فقدان القوة/ الإرهاق.</li></ul><p>التأثيرات الجانبية الشائعة (التي تصيب أقل من فرد واحد من أصل كل 10 أفراد) هي:</p><ul><li>آلام في البطن/ الغثيان.</li><li>سهولة حدوث نزيف/سهولة حدوث كدمات.</li><li>احمرار الجلد</li><li>سرعة ضربات القلب.</li><li>لطفح الجلدي/الشري</li><li>إفراز أجسام مضادة ل فبريف.</li></ul><p>أخبر طبيبك؛ إذا عانيت من أي تأثيرات جانبية. ويشمل ذلك أي تأثيرات جانبية محتملة، غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>يحفظ بعيدًا عن متناول الأطفال ومرآهم.</li><li>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العلبة الخارجية ومُلصق العبوة&nbsp;بعد اللفظة الإنجليزية&nbsp;EXP&nbsp;يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.&nbsp;</li><li>يحفظ في البراد (درجة الحرارة 2 إلى 8 درجة مئوية)</li><li>يجب عدم تجليد الدواء.</li><li>احفظ القارورة في العلبة الخارجية؛ لحمايتها من الضوء.</li><li>لا تستخدم الدواء &ndash; إذا كان لون المحلول متغيرًا، أو إذا كانت توجد به أجسام غريبة.</li><li>ينبغي استخدام المنتج الطبي على الفور. إذا لم يستخدم على الفور، يستخدم في غضون 24 ساعة، عند تخزينه في درجة حرارة تتراوح بين درجتين وثمان درجات مئوية بعيدًا عن الضوء.</li><li>يجب عدم التخلص من الأدوية في مياه الصرف الصحي أو في النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. تساهم هذه الإجراءات في حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>المادة الفعالة هي فيلاجلوسيراز ألفا</li></ul><p>تحتوي القارورة الواحدة، من المسحوق ذي ال 400 وحدة من ال فبريف على 400 وحدة من ال فيلاجلوسيراز ألفا بعد إعادة التشكيل، يحتوي كل مليليتر من المحلول على 100 وحدة من ال فيلاجلوسيراز ألفا</p><ul><li>المكونات الأخرى هي السكروز، صوديوم سيترات دايهايدرات، ستريك أسيد مونوهيدرات، وبوليسوربات 20 .</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <ul><li>إن فبريف هو مسحوق معد للتحليل من أجل الحق، لونه أبيض، أو أبيض مائل إلى الصفرة.</li><li>يجب أن يبدو المحلول صافيًا، أو داكنًا بعض الشيء،وعديم اللون قبل التخفيف، ولا تستخدمه إذا كان لونه متغيرًا، أو إذا كانت توجد به أجسام غريبة.</li><li>إن فبريف متوفر في قارورة زجاجية بسعة 20 مليليتر، تحتوي على 400 وحدة من ال فيلاجلوسيراز ألفا، على شكل مسحوق معد للتحليل من أجل الحقن.</li><li>تحتوي العلبة على قارورة واحدة، أو 5 قارورات، أو 25 قارورة.</li><li>قد لا يتم تسويق جميع أحجام العلب.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك رخصة التسويق</strong></p><p>,Shire Pharmaceutical Ireland ltd: Block 2 &amp; 3 Miesian Plaza<br />50-58Baggot Street Lower, Dublin 2, D02 Y754 , Ireland</p><p><strong>الجهات المصنعة</strong></p><p>Cangene bioPharma, Inc. (CBI), 1111 South Paca Street,<br />Baltimore, MD21230, USA<br />و<br />Vetter Pharma-Fertigung GmbH &amp; Co. KG<br />Mooswiesen 2, 88214 Ravensburg<br />Germany</p><p><strong>المصنع المسؤول عن فسح التشغيلة</strong></p><p>Shire Pharmaceutical Ireland</p><p>&nbsp;</p><p>لأي معلومات إضافية عن هذا الدواء أو للإبلاغ عن أي تأثيرات جانبية في لبنان وكل بلدان<br />الشرق الأوسط وشمال أفريقيا، الرجاء الاتصال بالممثل المحلي للشركة مالكة حق التسويق.<br />(Biologix FZ Co) شركة بيولوجيكس ف.ز كو وعنوانها :&nbsp;<br />المنطقة الحرة في دبي، الطريق WB 21 ، المستودع C 17 ، ص.ب54405<br />الطوار. دبي. الإمارات العربية المتحدة<br />أو على البريد الإلكتروني: Pharmacovigilance@blgx.net&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة للنص تمت في تاريخ يوليو 2017.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VPRIV 400 Units powder for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial contains 400 Units* of velaglucerase alfa**.
After reconstitution, one ml of the solution contains 100 Units of velaglucerase alfa.
*An enzyme unit is defined as the amount of enzyme that is required to convert one micromole of p-nitrophenyl β-D-glucopyranoside to p-nitrophenol per minute at 37ºC.
** produced in an HT-1080 human fibroblast cell line by recombinant DNA technology.
Excipients with known effect:
One vial contains 12.15 mg sodium.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion.
White to off-white powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for paediatric and adult patients with type 1 Gaucher disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VPRIV treatment should be supervised by a physician experienced in the management of patients with Gaucher disease. &nbsp;<br /><u>Posology</u><br />The recommended dose is 60 Units/kg administered every other week.&nbsp;<br />Dose adjustments can be made on an individual basis based on achievement and maintenance of therapeutic goals. Clinical studies have evaluated doses ranging from 15 to 60 Units/kg every other week. Doses higher than 60 Units/kg have not been studied.&nbsp;<br />Patients currently treated with imiglucerase enzyme replacement therapy for type 1 Gaucher disease may be switched to VPRIV, using the same dose and frequency.&nbsp;</p><p><u><em>Special populations</em></u><br /><em>Elderly (&ge;65 years old)&nbsp;</em><br />Elderly patients may be treated within the same dose range (15 to 60 units/kg) as other adult patients (see section 5.1).&nbsp;</p><p><em>Renal impairment&nbsp;</em><br />No dosing adjustment is recommended in patients with renal impairment based on current knowledge of the pharmacokinetics and pharmacodynamics of velaglucerase alfa (see section 5.2).&nbsp;<br /><em>Hepatic impairment&nbsp;</em><br />No dosing adjustment is recommended in patients with hepatic impairment based on current knowledge of the pharmacokinetics and pharmacodynamics of velaglucerase alfa (see section 5.2).</p><p><em>Paediatric population</em><br />Twenty of the 94 patients (21%) who received velaglucerase alfa during clinical studies were in the paediatric and adolescent age range (4 to 17 years). The safety and efficacy profiles were similar between paediatric and adult patients. See section 5.1 for further information.<br />The safety and efficacy of velaglucerase alfa in children below the age of 4 years have not yet been established. No data are available.&nbsp;<br />&nbsp;</p><p><u><em>Method of administration</em></u></p><p>For intravenous infusion use only. &nbsp;<br />To be administered as a 60-minute intravenous infusion.&nbsp;<br />Must be administered through a 0.2 or 0.22 &micro;m filter.&nbsp;<br />Home administration under the supervision of a healthcare professional may be considered only for those patients who have received at least three infusions and were tolerating their infusions well. Appropriate medical support, including adequately trained personnel in emergency measures, should be readily available when velaglucerase alfa is administered. If anaphylactic or other acute reactions occur, immediately discontinue the infusion and initiate appropriate medical treatment (see&nbsp;<br />section 4.4).&nbsp;<br />For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Severe allergic reaction to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p><u>&nbsp;</u>&nbsp;In order to improve the traceability of biological medicinal products, the name and batch number of the administered medicinal product should be clearly recorded.</p><p><strong><u>Hypersensitivity&nbsp;</u></strong><strong><u>Reactions Including Anaphylaxis:</u></strong></p><p>Hypersensitivity reactions, including symptoms consistent with anaphylaxis, have been reported in patients in clinical studies and in post-marketing experience. Patients were not routinely pre-medicated prior to infusion of VPRIV during clinical studies. The majority of hypersensitivity reactions usually occur up to 12&nbsp;hours post infusion. The most frequently reported symptoms of hypersensitivity include nausea, dizziness, hypotension, hypertension, rash dyspnoea, back pain, chest discomfort (including chest tightness), urticaria, arthralgia, fatigue/asthenia, pyrexia/body temperature increased and headache. Generally the reactions were mild and, in treatment-na&iuml;ve patients, onset occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. Additional hypersensitivity reactions of chest discomfort, dyspnea, pruritus and vomiting have been reported in post-marketing experience. As with any intravenous protein product, hypersensitivity reactions are possible, therefore appropriate medical support including personnel adequately trained in cardiopulmonary resuscitative measures and access to emergency measures should be readily available when VPRIV is administered. If anaphylactic or other acute reactions occur, immediately discontinue the infusion of VPRIV and initiate appropriate medical treatment.</p><p>The management of hypersensitivity reactions should be based on the severity of the reaction, e.g., slowing the infusion rate, treatment with medications such as antihistamines, antipyretics and/or corticosteroids, and/or stopping and resuming treatment with increased infusion time. In cases where patients have exhibited symptoms of hypersensitivity to the active ingredient or excipients in the drug product or to other enzyme replacement therapy, pre-treatment with antihistamines and/or corticosteroids may prevent subsequent reactions.</p><p><u><strong>Infusion related-reactions</strong></u><br />An infusion-related reaction is defined as any adverse drug reaction occurring within 24&nbsp;hours after the initiation of velaglucerase alfa infusion. Infusion‑related reactions (IRR) were the most commonly observed adverse reactions in patients treated in clinical studies. An IRR often appears as a hypersensitivity reaction. The most frequently reported symptoms of hypersensitivity include nausea, rash, dyspnoea, back pain, chest discomfort (including chest tightness), urticaria, arthralgia, and headache. Symptoms consistent with anaphylaxis have been reported in patients in clinical studies and in post-marketing experience. Apart from symptoms associated with hypersensitivity reactions IRRs might show as fatigue, dizziness, pyrexia, blood pressure increase, pruritus, vision blurred, or vomiting. In treatment-na&iuml;ve patients, the majority of infusion-related reactions occurred during the first 6&nbsp;months of treatment.</p><p><u>Prevention and management of infusion related reactions including hypersensitivity reactions</u></p><p>The management of infusion‑related reactions should be based on the severity of the reaction, and include slowing the infusion rate, treatment with medicinal products such as antihistamines, antipyretics and/or corticosteroids, and/or stopping and resuming treatment with increased infusion time.</p><p>Due to the risk for hypersensitivity reactions including anaphylaxis, appropriate medical support<em>,</em> including adequately trained personnel in emergency measures, should be readily available when velaglucerase alfa is administered. If anaphylactic or other acute reactions occur, in the clinic or home setting, immediately discontinue the infusion and initiate appropriate medical treatment. For patients developing anaphylaxis in a home setting it should be considered to continue treatment in a clinical setting.</p><p>Treatment should be approached with caution in patients who have exhibited symptoms of hypersensitivity to velaglucerase alfa or other enzyme replacement therapy.</p><p>Pre-treatment with antihistamines and/or corticosteroids may prevent subsequent reactions in those cases where symptomatic treatment was required.</p><p><u><strong>Immunogenicity</strong></u><br />Antibodies may play a role in treatment-related reactions found with the use of velaglucerase alfa. To further evaluate the relationship, in cases of severe infusion-related reactions and in cases of lack or loss of effect patients should be tested for the presence of antibodies and the results reported to the company.</p><p>In the clinical studies for Marketing Authorisation one of 94&nbsp;(1%)&nbsp;patients developed IgG-class antibodies to velaglucerase alfa. In this one event, the antibodies were determined to be neutralising in an <em>in vitro</em> assay.</p><p>- No patients developed IgE antibodies to velaglucerase alfa.</p><p>&nbsp;- No infusion related reactions were reported.</p><p><em>Post-marketing phase</em></p><p>During a post marketing extension study, one patient developed IgG antibodies to VPRIV. In addition, a few events of positive neutralising antibodies and lack of effect were reported post marketing.</p><p><u>Sodium</u></p><p>This medicinal product contains 12.15&nbsp;mg sodium per vial. This is equivalent to 0.6% of the WHO recommended maximum daily intake of 2&nbsp;g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Women of child bearing potential</strong></u><br />Patients who have Gaucher disease and become pregnant may experience a period of increased disease activity during pregnancy and the puerperium. A risk-benefit assessment is required for each pregnancy. Close monitoring of the pregnancy and clinical manifestations of Gaucher disease is necessary for the individualisation of therapy.<br /><u><strong>Pregnancy</strong></u><br />Pregnancy Category C.<br />There are no data from the use of velaglucerase alfa in pregnant women.<br />Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women.<br /><u><strong>Breast-feeding</strong></u><br />There are no data from studies in breast-feeding women. It is not known whether velaglucerase alfa is excreted in human milk. Because many active substances are excreted in human milk, caution should be exercised when prescribing to a breast-feeding woman.<br /><u><strong>Fertility</strong></u><br />Animal studies show no evidence of impaired fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VPRIV has no or negligible influence on the ability to drive or use machines.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The data described below reflect exposure of 94 patients with type 1 Gaucher disease who received velaglucerase alfa at doses ranging from 15 to 60 Units/kg every other week in 5 clinical studies.<br />Fifty-four patients were na&iuml;ve to ERT and 40 patients switched from imiglucerase to VPRIV. Patients were between 4 and 71 years old at the time of first treatment with VPRIV, and included 46 male and 48 female patients.</p><p>The most serious adverse reactions in patients in clinical trials were hypersensitivity reactions.</p><p>The most common adverse reactions were infusion-related reactions. The most commonly observed symptoms of infusion-related reactions were: headache, dizziness, hypotension, hypertension, nausea, fatigue/asthenia, and pyrexia/body temperature increased (see section 4.4 for further information). The only adverse reaction leading to discontinuation of treatment was an infusion-related reaction.</p><p>Adverse reactions reported in patients with type 1 Gaucher disease are listed in Table 1. Information is presented by system organ class and frequency according to MedDRA convention. Frequency is defined as very common (1/10) and common (1/100 to &lt;1/10). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p><strong>Table 1: Adverse reactions reported with VPRIV observed in patients with type 1 Gaucher<br />disease</strong></p><p><img alt="" width="700" height="408" src="data:image/png;base64,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" /></p><p><u>Paediatric population</u><br />The safety profile of VPRIV in clinical studies involving children and adolescents aged 4 to 17 years was similar to that observed in adult patients.</p><p><br /><u>Elderly population (&ge;65yrs)</u><br />The safety profile of VPRIV in clinical studies involving patients aged 65 years and above was similar to that observed in other adult patients.</p><p>&nbsp;</p><p><strong><u>Reporting of suspected adverse reactions</u></strong>&nbsp;<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed below:&nbsp;</p><p>&middot;<em>Saudi A</em><em>rabia:</em>&nbsp;</p><p><u>Please report adverse drug events to: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; <em>Other GCC states:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited information available regarding overdose with velaglucerase alfa. In the majority of the cases reporting overdose, no additional adverse events were observed. However, in the event of accidental or intentional overdose, patients should be carefully observed and treatment should be symptomatic and supportive. There is no antidote available. The maximum dose of velaglucerase alfa in clinical studies was 60 Units/kg (see section 4.4).&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other alimentary tract and metabolism products &ndash; enzymes, ATC code: A16A B10.</p><p>Gaucher disease is an autosomal recessive disorder caused by mutations in the GBA gene which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. This enzymatic deficiency causes an accumulation of glucocerebroside primarily in macrophages, giving rise to foam cells or &quot;Gaucher cells&quot;. In this lysosomal storage disorder (LSD), clinical features are reflective of the distribution of Gaucher cells in the liver, spleen, bone marrow, skeleton, and lungs. The accumulation of glucocerebroside in the liver and spleen leads to organomegaly. Bone involvement results in skeletal abnormalities and deformities as well as bone pain crises. Deposits in the bone marrow and splenic sequestration lead to clinically significant anaemia and thrombocytopenia.</p><p>The active substance of VPRIV is velaglucerase alfa, which is produced by gene activation technology in a human cell line. Velaglucerase alfa is a glycoprotein. The monomer is approximately 63 kDa, has 497 amino acids, and the same amino acid sequence as the naturally occurring human enzyme, glucocerebrosidase. There are 5 potential N-linked glycosylation sites, four of which are occupied. Velaglucerase alfa is manufactured to contain predominantly high-mannose-type glycans to facilitate internalisation of the enzyme by the phagocytic target cells via the mannose receptor.</p><p>Velaglucerase alfa supplements or replaces beta-glucocerebrosidase, the enzyme that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide in the lysosome, reducing the amount of accumulated glucocerebroside and correcting the pathophysiology of Gaucher disease. Velaglucerase alfa increases haemoglobin concentration and platelet counts and reduces liver and spleen volumes in patients with type 1 Gaucher disease.</p><p>In Studies 025EXT and 034, patients were offered home therapy. In Study 025EXT, 7 of 10 patients received home therapy at least once during 60 months of treatment. In Study 034, 25 of 40 patients received home therapy at least once during the 12-month study.</p><p><u>Clinical efficacy and safety<br /><em>Studies in treatment na&iuml;ve patients</em></u><br />Study 025 was a 9 month, open-label study in 12 adults (&ge;18 years) patients who were na&iuml;ve to ERT (defined as having not been treated with ERT for at least 12 months prior to study entry). VPRIV was initially administered in a dose-escalating fashion in the first 3 patients (15, 30, 60 Units/kg) and the 9 remaining patients began treatment with 60 Units/kg.</p><p>Clinically meaningful improvements from baseline were observed in haemoglobin concentration and platelet counts as early as 3 months and in liver and spleen volumes at both 6 months and 9 months following the initiation of treatment with VPRIV.</p><p>Ten patients who completed Study 025 enrolled in an open-label extension study (025EXT). After a minimum of 12 months of continuous treatment with VPRIV, all patients qualified to have the dose of VPRIV reduced in a step-wise fashion from 60 to 30 Units/kg after achieving at least 2 of the 4 &ldquo;Year 1&rdquo; therapeutic goals of ERT for type 1 Gaucher disease. Patients received doses ranging from 30 to 60 Units/kg (median dose 35 Units/kg) every other week for up to 60 months (5 years). Sustained clinical activity continued to be demonstrated during 5 years of treatment as observed by improvements in haemoglobin concentrations and platelet counts and reduced liver and spleen volumes.</p><p>Study 032 was a 12-month, randomized, double-blind, parallel-group efficacy study in 25 patients aged 2 years and older who were na&iuml;ve to ERT (defined as having not been treated with ERT for at least 30 months prior to study entry). Patients were required to have Gaucher disease-related anaemia and either thrombocytopenia or organomegaly. Patients were randomized to receive VPRIV at a dose of either 45 Units/kg (N=13) or 60 Units/kg (N=12) every other week.</p><p>Velaglucerase alfa 60 Units/kg given IV every other week demonstrated clinically meaningful increases from baseline in mean haemoglobin concentration (+2.4 g/dl) and platelet count (+50.9 x 109/l), liver volume was reduced from 1.46 to 1.22 times normal (mean reduction of 17%) and spleen volume was reduced from 14.0 to 5.75 times normal (mean reduction of 50%). Meaningful&nbsp;increases from baseline were observed in the 45 Units/kg dose group in haemoglobin concentration (+2.4 g/dl) and platelet count (+40.9 x 109/l), liver volume was reduced from 1.40 to 1.24 times normal (mean reduction of 6%) and spleen volume was reduced from 14.5 to 9.50 times normal (mean reduction of 40%).</p><p>Study 039 was a 9-month, randomized, double-blind, non-inferiority, active-comparator (imiglucerase) controlled, parallel-group efficacy study in 34 patients aged 2 years and older who were na&iuml;ve to ERT (defined as having not been treated with ERT for at least 12 months prior to study entry). Patients were required to have Gaucher disease-related anaemia and either thrombocytopenia or organomegaly. Patients received either 60 Units/kg of VPRIV (N=17) or 60 Units/kg of imiglucerase (N=17) every other week.</p><p>The mean absolute increase from baseline in haemoglobin concentrations was 1.624 g/dl (&plusmn;0.223 SE) following 9 months of treatment with VPRIV. This increase in haemoglobin concentration was demonstrated to be clinically and statistically non-inferior to imiglucerase (mean treatment difference of change from baseline to 9 months [VPRIV &ndash; imiglucerase]: 0.135 g/dl). There were no statistically significant differences between VPRIV and imiglucerase in changes in platelet counts and liver and spleen volumes after 9 months of VPRIV treatment, and in the time to first haemoglobin response (defined as 1 g/dl increase from baseline).</p><p><u>Study in patients switching from imiglucerase treatment to VPRIV</u><br />Study 034 was a 12-month, open-label safety study in 40 patients aged 2 years and older who had been receiving treatment with imiglucerase at doses ranging from 15 to 60 Units/kg for a minimum of 30 consecutive months. Patients were required to have a stable dose of imiglucerase for at least 6 months prior to study enrolment. Treatment with VPRIV was administered as the same number of units and regimen as their imiglucerase dose. Haemoglobin concentration and platelet counts were evaluated as changes from baseline, which was defined as the end of the patient&rsquo;s treatment with imiglucerase.</p><p>In patients who switched from imiglucerase to VPRIV, haemoglobin concentrations and platelet counts were sustained at therapeutic levels through 12 months of treatment.</p><p>Study 058 was an open-label clinical safety study in 211 patients including 205 patients previously treated with imiglucerase 6 treatment-na&iuml;ve patients and 57 patients aged 65 years or older (56/57 had switched from imiglucerase to VPRIV). Patients transferring from imiglucerase were administered VPRIV infusions every other week at the same number of units as imiglucerase within the range of 15 to 60 U/kg. Patients transferring from a dose of &lt;15 U/kg imiglucerase were administered 15 U/kg of<br />VPRIV.<br />Patients previously treated with imiglucerase received a median of 8 VPRIV infusions with median duration of treatment of 15.1 weeks. The safety profile in these patients was similar to that observed in other clinical trials. Only 1 out of 163 patients assessed developed anti-velaglucerase alfa antibodies during the study.</p><p>The mean haemoglobin concentration and platelet count of patients previously treated with imiglucerase were maintained throughout the study and remained within the reference intervals.<br /><u>Paediatric population</u><br />Use in the age group 4 to 17 is supported by evidence from controlled studies in adults and paediatric [20 of 94 (21%)] patients. The safety and efficacy profiles were similar between paediatric and adult patients. The studies allowed the inclusion of patients 2 years and older and the safety and efficacy profiles are expected to be similar down to the age of 2 years. However, no data are available for children under the age of 4 years.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with VPRIV in all subsets of the paediatric population with type 2 Gaucher disease and has deferred the obligation to submit the results of studies with VPRIV in one or more subsets of the paediatric population in Gaucher disease type 1 and 3, as per the PIP decision.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There were no apparent pharmacokinetic differences between male and female patients with type 1 Gaucher disease. None of the subjects in the pharmacokinetic studies were positive for anti-velaglucerase alfa antibodies on the days of pharmacokinetic evaluation. Therefore, it was not possible to evaluate the effect of antibody response on the pharmacokinetic profile of velaglucerase alfa.</p><p><strong>Absorption</strong><br />Velaglucerase alfa serum concentrations rose rapidly for the first 20 minutes of the 60-minute infusion before leveling off, and Cmax was typically attained between 40 and 60 minutes after the start of the infusion. After the end of the infusion, velaglucerase alfa serum concentrations fell rapidly in a monophasic or biphasic fashion with a mean t1/2 ranging from 5 to 12 minutes at doses of 15, 30, 45, and 60 Units/kg.</p><p><strong>Distribution</strong><br />Velaglucerase alfa exhibited an approximately linear (i.e. first-order) pharmacokinetic profile, and Cmax and AUC increased approximately proportional to the dose over the dose range 15 to 60 Units/kg. The steady state volume of distribution was approximately 10% of the body weight. The high clearance of velaglucerase alfa from serum (mean 6.7 to 7.6 ml/min/kg) is consistent with the rapid uptake of velaglucerase alfa into macrophages via mannose receptors.<br />&nbsp;</p><p><strong>Elimination</strong><br />The range of velaglucerase alfa clearance in paediatric patients (N=7, age range 4 to 17 years) was contained within the range of clearance values in adult patients (N=15, age range 19 to 62 years).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, and toxicity to reproduction and development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sucrose<br />Sodium citrate dihydrate (E331)<br />Citric acid monohydrate (E330)<br />Polysorbate 20</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator ( 2<sup>o</sup>C to 8<sup>o</sup>C).<br />Do not freeze.<br />Keep the vial in the outer carton in order to protect from light.</p><p>From a microbiological point of view, the medicinal product should be used immediately. If not used<br />immediately, in-use storage times and conditions prior to use are the responsibility of the user and<br />must not exceed 24 hours at 2<sup>o</sup>C to 8<sup>o</sup>C.</p><p>Reconstituted and diluted solution for infusion:<br />Chemical and physical in-use stability has been demonstrated for 24 hours at 2<sup>o</sup>C to 8<sup>o</sup>C under protection from light.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>20 ml vial (type I glass) with a stopper (fluoro-resin coated butyl rubber), one piece seal, and flip-off cap, containing 400 Units of velaglucerase alfa in powder. Pack sizes of 1, 5 and 25 vials.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VPRIV requires reconstitution and dilution, and is intended for intravenous infusion only. VPRIV is<br />for single-use only and is administered through a 0.22 &mu;m filter.<br />Use aseptic technique.<br />Prepare VPRIV as follows:<br />1. The number of vials to be reconstituted is determined based on the individual patient&rsquo;s weight and the prescribed dose.<br />2. The required vials are removed from the refrigerator. Each 400 Units vial is reconstituted with<br />4.3 ml of sterile water for injections.<br />3. Upon reconstitution, mix vials gently. Do not shake. Each vial will contain an extractable volume of 4.0 ml (100 Units/ml).<br />4. Prior to further dilution, visually inspect the solution in the vials; the solution should be clear to slightly opalescent and colourless; do not use if the solution is discoloured or if foreign particulate matter is present.<br />5. The calculated volume of medicinal product is withdrawn from the appropriate number of vials<br />and the total volume required is diluted in 100 ml of sodium chloride 9 mg/ml (0.9%) solution for infusion. Mix gently. Do not shake. The infusion should be initiated within 24 hours from the time of reconstitution.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Takeda Pharmaceuticals International AG Ireland Branch, 
Block 3 Miesian Plaza, 50 - 58 Baggot Street Lower, 
Dublin 2, Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                15 April 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>